Published in Gene Therapy Weekly, June 19th, 2003
According to a study from the United States, "T-cell dysfunction is thought to be central to the immunodeficiency state seen in patients with the Wiskott-Aldrich syndrome (WAS). Aspects of the WAS phenotype have been corrected in other cell types on introduction of the normal WAS protein (WASP), but the potential for correction of the T-cell defects has not been evaluated."
"Here we demonstrate that an oncoretroviral vector encoding WASP and green fluorescent protein (GFP) and pseudotyped with the RD114 envelope protein efficiently transduces primary human T cells derived...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.